Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2a Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of KAN-101 In Participants With Celiac Disease

NCT06001177 is registered in ClinicalTrials.gov with Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion SA as lead sponsor.

NCT NCT06001177
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06001177 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2a Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of KAN-101 In Participants With Celiac Disease
Lead sponsor
Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion SA
Phase
Phase 2
Overall status
Completed
Start date
December 13, 2023
Completion date
January 13, 2025
Enrollment
55 (actual)
Sites
28

Conditions

As the registry lists them; a condition with its own page is linked.

celiac disease, coeliac disease